Page 6 - Randomized Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer

SHANGHAI, China, Jan. 17, 2024 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading…

New yorkUnited statesUnited kingdomSan franciscoBarbara shecterTiff macklemJunshi biosciencesZhi liJoe oconnorGabriel friedmanPerioperative toripalimabAmerican society of clinical oncologyAustralia therapeutic goods administrationEuropean medicines agencyShanghai junshi biosciences co ltdNational post

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine

Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesUnited kingdomJunshi biosciencesZhi liRegulatory agencyDrug administrationAustralia therapeutic goods administrationChinese society of clinical oncologyNational reimbursement drug listNational medical products administrationShanghai junshi biosciences co ltdEuropean medicines agencyIr teamGlobal researchPr team

Oncolytics Biotech® Inc : Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024

Oncolytics Biotech® Inc : Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United statesMatt coffeyTimothy mccarthyJon pattonThomas heinemanCompany contactOncolytics biotech incSecurities exchangeMetastatic breast cancer programAmerican society of clinical oncologyOncolytics biotechEuropean society for medical oncologyInternational multidisciplinary anal cancer conferencePancreatic cancer action network panChief executive officerTranslational data

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS - BriaCell Therapeutics (NASDAQ:BCTXW), BriaCell Therapeutics (NASDAQ:BCTX)

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*).32 out of 42 patients treated since 2022

United statesBritish columbiaUnited kingdomSan antonioCarmen calfaWilliamv williamsJules abrahamHenryb gonzalez convention centerNeither the toronto stock exchangeCompany contactBriacell therapeutics corpUniversity of miami miller school medicineClinical researchRegulation services providerToronto stock exchangeExchange commission

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San antonioUnited statesBritish columbiaUnited kingdomCarmen calfaWilliamv williamsHenryb gonzalez convention centerToronto stock exchangeCompany contactExchange commissionClinical researchUniversity of miami miller school medicineNeither the toronto stock exchangeRegulation services providerBriacell therapeutics corpCell therapeutics